These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11575988)

  • 1. Anaphylactic reaction to ondansetron.
    Weiss KS
    Arch Intern Med; 2001 Oct; 161(18):2263. PubMed ID: 11575988
    [No Abstract]   [Full Text] [Related]  

  • 2. Generalised seizures following ondansetron.
    Sharma A; Raina V
    Ann Oncol; 2001 Jan; 12(1):131-2. PubMed ID: 11249042
    [No Abstract]   [Full Text] [Related]  

  • 3. Ondansetron: reasons to be restrictive.
    Frigerio C; Buchwalder PA; Spertini F
    Lancet; 1996 May; 347(9013):1484-5. PubMed ID: 8676652
    [No Abstract]   [Full Text] [Related]  

  • 4. Anaphylactoid reaction due to the administration of ondansetron in a pediatric neurosurgical patient.
    Ross AK; Ferrero-Conover D
    Anesth Analg; 1998 Oct; 87(4):779-80. PubMed ID: 9768769
    [No Abstract]   [Full Text] [Related]  

  • 5. Anaphylaxis to an ondansetron wafer.
    Tan J; Mehr S
    J Paediatr Child Health; 2012 Jun; 48(6):543-4. PubMed ID: 21679335
    [No Abstract]   [Full Text] [Related]  

  • 6. Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis.
    Parikh PM; Shah SR; Shah SC; Sheth V; Patel RA; Shah KC; Jain PK
    Indian J Cancer; 1996 Mar; 33(1):17-20. PubMed ID: 9063013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
    Lofters WS; Pater JL; Zee B; Dempsey E; Walde D; Moquin JP; Wilson K; Hoskins P; Guevin RM; Verma S; Navari R; Krook JE; Hainsworth J; Palmer M; Chin C
    J Clin Oncol; 1997 Aug; 15(8):2966-73. PubMed ID: 9256141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed diagnosis of anaphylaxis secondary to ondansetron: A case report.
    Goyal P; Paramesh K; Puranik S; Proctor M; Sanghvi M
    Eur J Anaesthesiol; 2016 Feb; 33(2):146-7. PubMed ID: 26555872
    [No Abstract]   [Full Text] [Related]  

  • 9. Anaphylactic reaction owing to ondansetron administration in a child with neuroblastoma and safe use of granisetron: a case report.
    Demir HA; Batu ED; Yalçın B; Civelek E; Saçkesen C; Büyükpamukçu M
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):e341-2. PubMed ID: 20921907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous cortisol exerts antiemetic effect similar to that of exogenous corticosteroids.
    Hursti TJ; Fredrikson M; Steineck G; Börjeson S; Fürst CJ; Peterson C
    Br J Cancer; 1993 Jul; 68(1):112-4. PubMed ID: 8318400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated urticaria to ondansetron and successful treatment with granisetron.
    Bousquet PJ; Co-Minh HB; Demoly P
    Allergy; 2005 Apr; 60(4):543-4. PubMed ID: 15727597
    [No Abstract]   [Full Text] [Related]  

  • 13. Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study.
    Shi Y; He X; Yang S; Ai B; Zhang C; Huang D; Dong M; Liu P; Zhou S; Han X
    Chemotherapy; 2007; 53(1):44-50. PubMed ID: 17202811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ondansetron anaphylaxis: a case report and protocol for skin testing.
    Fernando SL; Broadfoot AJ
    Br J Anaesth; 2009 Feb; 102(2):285-6. PubMed ID: 19151059
    [No Abstract]   [Full Text] [Related]  

  • 15. Fixed drug eruption secondary to ondansetron.
    Iglesias ME; España A; Redondo P; Quintanilla E
    Dermatology; 1995; 191(3):270-1. PubMed ID: 8534955
    [No Abstract]   [Full Text] [Related]  

  • 16. Two cases of recurrent priapism during antineoplastic chemotherapy: think about ondansetron.
    Pivot D; Javot L; Swiegot D; Petitpain N; Spaëth D; Trechot P
    Therapie; 2013; 68(6):409-10. PubMed ID: 24246123
    [No Abstract]   [Full Text] [Related]  

  • 17. Extrapyramidal reaction caused by ondansetron.
    Mathews HG; Tancil CG
    Ann Pharmacother; 1996 Feb; 30(2):196. PubMed ID: 8835061
    [No Abstract]   [Full Text] [Related]  

  • 18. Anaphylactoid reactions associated with ondansetron.
    Kossey JL; Kwok KK
    Ann Pharmacother; 1994 Sep; 28(9):1029-30. PubMed ID: 7803876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of prophylactic ondansetron in patients undergoing modified radical mastectomy.
    Sadhasivam S; Saxena A; Kathirvel S; Kannan TR; Trikha A; Mohan V
    Anesth Analg; 1999 Dec; 89(6):1340-5. PubMed ID: 10589605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical usefulness of ondansetron injection in patients receiving cancer chemotherapy].
    Furue H; Ikeda M; Tsukagoshi S; Taguchi T; Fujii T; Rikimaru T
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):261-71. PubMed ID: 11865633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.